Research Paper Volume 14, Issue 8 pp 3597—3606

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer

class="figure-viewer-img"

Figure 2. The BET inhibitor JQ1 suppresses KRAS mutant pancreatic cancer cells. (A) The structure of the BET inhibitor JQ1. (B) Fitting curve of cytostatic responses illustrated a decreasing concentration gradient of JQ1 treated with 7 KRAS mutant pancreatic cancer cell lines (AsPC-1, MIA PaCa-2, PANC-1, HuP-T4, HuP-T3, PSN1, and CFPAC-1).